From Precision Medicine Online
NEW YORK – Triumvira Immunologics said on Thursday it had begun treating patients in a Phase II trial of its autologous T-cell therapy, TAC01-HER2, in HER2-positive gastric and gastroesophageal junction cancers.
The firm began the potentially registrational Phase II portion of the TACTIC-2 study, which is evaluating TAC01-HER2 as a monotherapy and in combination with Merck’s Keytruda (pembrolizumab) in HER2-positive gastric cancers. Deyaa Adib, chief medical officer of Triumvira Immunologics, said in a statement that these tumor types were identified based on positive results from the Phase I portion of the study in solid tumors.
